Immunochemical relatedness among pituitary follicle-stimulating hormones of tetrapod vertebrates.

An antiserum generated against ovine follicle-stimulating hormone (FSH) was used to examine phylogenetic relatedness of FSH molecules among the four classes of tetrapods. Heterologous radioimmunoassay (RIA) employing this antiserum with ¹²⁵I-labeled human FSH as tracer revealed a high degree of immunochemical similarity among purified FSH molecules from diverse eutherian, metatherian, avian, and reptilian species. While the eutherian hormones tended to be slightly more potent than those from other amniotes, at least one avian FSH (ostrich) exhibited an equivalent degree of antigenicity. Hormones from amphibians formed a discrete group with lower cross-reactivity. In all of these species, only the gonadotropin previously identified as an FSH on the basis of physicochemical and biological profiles showed appreciable cross-reactivity; LH preparations were essentially inactive. ¹²⁵I-Labeled FSH from a bird (turkey), reptile (sea turtle), and amphibian (bullfrog) bound specifically to the anti-ovine FSH serum, and RIAs with these as tracers yielded essentially the same results as outlined above. Immunoneutralization tests employing binding of ¹²⁵I-labeled hormone to gonadal receptors confirmed that the anti-ovine FSH serum cross-reacted with the biologically active form of the FSH from the human, bird, and turtle. Moreover, the antiserum appeared to preferentially bind to that portion of the radiolabeled hormone that exhibited the greatest capacity to bind to tissues. The squamate reptiles (snakes and lizards) presented a striking exception to the above phylogenetic patterns, since no antigenic cross-reactivity could be detected with the pituitaries or purified gonadotropins from these reptiles.     

Hematologic and immunomodulatory effects of an interleukin-1 receptor antagonist coinfusion during low-dose endotoxemia in healthy humans

Endotoxin is a component of gram-negative bacteria that causes hematologic and immunologic changes through its induction of cytokines. Interleukin-1 receptor antagonist (IL-1Ra) is a naturally occurring inhibitor of IL-1 that competes with IL-1 for occupancy of cell-surface receptors but possesses no agonist activity. We investigated the ability of human recombinant IL-1Ra to block the effects of low-dose endotoxin. Fourteen healthy male volunteers between 18 and 30 years old were injected intravenously with 3 ng/kg Escherichia coli endotoxin. Concurrent with the injections, nine volunteers received a 3-hour continuous intravenous infusion of IL-1Ra. The other five subjects were given a 3-hour infusion of saline. Volunteers injected with endotoxin experienced a threefold increase in circulating neutrophils over baseline. This neutrophilia was significantly reduced by 48% in subjects administered endotoxin plus IL-1Ra (P = .0253). Ex vivo mitogen-induced peripheral blood mononuclear cell proliferation decreased by greater than 60% at 3 and 6 hours after endotoxin injection (P = .0053). This endotoxin-induced reduction in mitogen response was reversed in subjects coinjected with IL-1Ra (P = .0253). Endotoxin-induced symptoms, fever, and tachycardia were unaffected by IL-1Ra. IL-1 appears to be an important mediator in endotoxemia because some of its hematologic and immunomodulatory effects can be blocked by IL-1Ra.     

Effects of gonadectomy and sex steroids on pituitary gonadotrophin release and response to gonadotrophin-releasing hormone (GnRH) agonist in the bullfrog, Rana catesbeiana

Gonadectomy of adult bullfrogs, Rana catesbeiana, elevated plasma levels of both follicle-stimulating hormone (FSH) and luteinizing hormone (LH). Profiles of plasma gonadotrophins after gonadectomy were similar in the two sexes; however, FSH increased faster in females than males. Both gonadotrophins continued to rise for several months and remained elevated after 1 year, but there was some dissociation between the two hormones; FSH increased sooner (1 week vs 3 weeks), reached higher levels (FSH/LH much greater than 1), and did not show the secondary decline exhibited in LH. Similarly, in subadult males and females, gonadectomy increased plasma FSH by 1 week but LH levels were less affected. Postgonadectomy increases in both gonadotrophins were prevented by chronic (6-week) implantation of capsules containing estradiol-17 beta (E2) or 5 alpha-dihydrotestosterone (DHT), and treatment with DHT and E2 within physiological ranges starting 1 year after gonadectomy also suppressed chronically elevated levels of plasma gonadotrophins. Compared to untreated gonadectomized frogs, the rate of increase in both plasma gonadotrophins. Compared to untreated gonadectomized frogs, the rate of increase in both plasma gonadotrophins was accelerated after removal of DHT at 6 weeks. Acute pituitary responsiveness to a gonadotrophin-releasing hormone (GnRH) agonist was markedly reduced in short-term (3.5-8 weeks) gonadectomized subadult males (but not females) and in long-term (1 year) gonadectomized males and females. Treatment with E2 had no effect on GnRH responsiveness in these frogs, but DHT implants significantly enhanced the response to agonist in both sexes. Thus, the nonaromatizable androgen--DHT--may have both negative feedback effects (at the hypothalamic level) and positive effects at the level of the pituitary, whereas, estrogen exhibited only the former, negative feedback activity. Sex differences in circulating DHT, which are detectable even in juveniles, may account for the sexual dimorphism in pituitary responsiveness to GnRH in the bullfrog.     

Degradation of tissue-type plasminogen activator by human monocyte- derived macrophages is mediated by the mannose receptor and by the low- density lipoprotein receptor-related protein

The balance of tissue-type plasminogen activator (t-PA) production and degradation determines its concentration in blood and tissues. Disturbance of this balance may result in either increased or decreased proteolysis. In the present study, we identified the receptor systems involved in the degradation of t-PA by human monocytes/macrophages in culture. Monocytes were cultured and became macrophages within 2 days. At 4 degrees C, 125I-t-PA bound to macrophages with high (apparent dissociation constant [kd], 1 to 5 nmol/L) and low affinity (kd > 350 nmol/L). At 37 degrees C, the cells internalized and degraded t-PA via the high affinity binding sites, which were partially inhibited by mannan. The low affinity binding sites were 6-aminohexanoic acid- inhibitable and not involved in t-PA degradation. Degradation of t-PA was upregulated during differentiation of monocytes to macrophages. Dexamethasone further upregulated the mannan-inhibitable t-PA degradation. Lipopolysaccharide downregulated both mannan-inhibitable and non-mannan-inhibitable t-PA degradation. Non-mannan-inhibitable degradation was completely blocked by recombinant 39-kD receptor- associated protein (RAP, inhibitor of lipoprotein receptor-related protein [LRP]), whereas mannan-inhibitable degradation was blocked by the addition of a monoclonal antibody against the mannose receptor. No differences between the degradation of t-PA and functionally inactivated t-PA were observed. We conclude that human monocyte-derived macrophages are able to bind, internalize, and degrade t-PA. Degradation of t-PA does not require complex formation with plasminogen activator inhibitors. The macrophages use two independently regulated receptors, namely, the mannose receptor and LRP, for the uptake and degradation of t-PA.     

Systemic use of non‐biologic corticosteroids in orofacial diseases

Systemic non‐biologic agents have long been in clinical use in medicine – often with considerable efficacy, albeit with some adverse effects – as with all medications. With the advent of biologic agents, all of which currently are restricted to systemic use, there is a growing need to ensure which agents have the better therapeutic ratio. The non‐biologic agents (NBAs) include a range of agents, most especially the corticosteroids (corticosteroids). This study reviews the corticosteroids in systemic use in management of orofacial mucocutaneous diseases; subsequent studies discuss corticosteroid‐sparing agents used in the management of orofacial diseases, such as calcineurin inhibitors used to produce immunosuppression; purine synthetase inhibitors; and cytotoxic and other immunomodulatory agents.